Reports Q4 revenue $305.4M, consensus $311.1M. "Looking back at 2022, I am proud of our team for delivering another year of above-market, net sales growth," said Chris Barry, CEO. "Looking ahead, I couldn’t be more excited to join forces with Globus Medical to create a leading, global musculoskeletal technology company. Our complementary commercial organizations and product portfolios make a strong financial profile and value creation opportunity for shareholders-while furthering our ability to increase customer reach and change more patient lives."
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on NUVA:
- NuVasive Announces Fourth Quarter and Full-Year 2022 Financial Results and 2023 Net Sales Guidance
- Globus Medical price target lowered to $75 from $82 at Barclays
- Globus Medical downgraded to Underperform from Buy at BofA
- Globus Medical downgraded to Equal Weight from Overweight at Wells Fargo
- NuVasive downgraded to Equal Weight from Overweight at Wells Fargo